Dave Ricks, CEO of Eli Lilly, speaks within the Oval Workplace throughout an occasion about weight reduction medicine on the White Home in Washington, Nov. 6, 2025.
Andrew Caballero-Reynolds | AFP | Getty Pictures
Eli Lilly opposes the White Home’s push to codify “most favored nation” drug pricing into legislation, CEO Dave Ricks stated in an interview with CNBC.
Lilly is one in every of greater than a dozen drugmakers that signed offers with the Trump administration final yr agreeing to cost related costs for prescribed drugs within the U.S. as in different rich nations. President Donald Trump has lengthy complained that People pay excessive costs to subsidize low costs for medication in the remainder of the world.
The pharmaceutical business thought the agreements would pacify these considerations and thwart makes an attempt to make “most favored nation” pricing the legislation. However the White Home in current months has pushed Congress to codify parts of the offers. The draft textual content hasn’t been shared publicly, although the administration has stated it is making an attempt to get pharmaceutical corporations to again the trouble.
Lilly would not assist it, Ricks stated.
“If you throw it into the congressional course of, what goes in isn’t what is going on to return out,” Ricks stated. “And I believe we see lots of people who would somewhat cut back costs at present and never fear about whether or not we now have any new medicines tomorrow, not fear about whether or not America could have a strong drug business and we’ll be capable to do analysis on this nation. And I fear about these issues, so I do not assume that is an incredible concept, and we have been fairly clear with the administration and the congressional leaders about that.”
Ricks stated he thinks the Trump administration and management on the Hill are listening to the corporate’s considerations, however he stated Lilly will use “all of the instruments we now have to fight unhealthy coverage, and we predict it will be unhealthy coverage.”
